Combined Oral Contraceptive Use Increases HPV Persistence but Not New HPV Detection in a Cohort of Women From Thailand

Marks, Morgan A.; Gravitt, Patti E.; Gupta, Swati; Liaw, Kai Li; Tadesse, Amha; Kim, Esther; Phongnarisorn, Chailert; Wootipoom, Virach; Yuenyao, Pissimai; Vipupinyo, C.; Sriplienchan, Somchai; Celentano, David D.

doi:10.1093/infdis/jir560

Cited by 35 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies assessing the risk of incident HPV infection and OC use have also been inconsistent. Our findings indicate that lifetime OC use has a protective effect against HR-HPV acquisition and is in line with similar studies [13,18], yet others report no association between OC use and incident HPV infection or even increased risk [19-22]. …”

Section: Discussionsupporting

confidence: 93%

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica

et al. 2013

View full text Add to dashboard Cite

BackgroundHigh risk human papillomaviruses (HR-HPV) are known to be extremely common, sexually transmitted infections, but more information is needed regarding the absolute risks of type-specific HR-HPV infections in the years following sexual debut.MethodsWe conducted a survival analysis of 3,737 women aged 18–25 from the control group of the Costa Rican Vaccine trial to determine the absolute risks of HR-HPV infections at 12 months, 24 months, and end of follow-up (average of 50.7 months). To corroborate determinants of infection, we used Cox proportional hazards methods to assess associations between demographics and sexual risk behaviors and incident HR-HPV.ResultsCumulative incidence for HR-HPV infections was 51.3% at the end of the study period. The most common incident types were HPV52 (15.4%), HPV51 (13.6%), and HPV16 (12.4%). Type-specific cumulative incidence corresponded closely with type-specific prevalences, except that HPV16 was more prevalent than predicted by incidence, suggesting greater persistence. The strongest predictors of incident HR-HPV infections as a group in a multivariate analysis were the expected correlates of sexual behavior of the woman and her partner, such as being single (HR 1.6, 95% CI 1.4-1.8) or divorced/widowed (HR: 2.1, 95% CI: 1.7-2.7), having multiple HPV infections at enrollment (HR: 1.5, 95% CI: 1.3-1.7), and current smoking (HR: 1.2, 95% CI: 1.0-1.3). In women who reported being having only one lifetime sexual partner (being in a monogamous relationship), the strongest predictors of HR-HPV included not living with sex partner (HR: 2.1, 95% CI 1.7-2.5) and age of sex partner (HR: 1.4, 95% CI: 1.0-1.8).ConclusionWe confirm the extremely high incidence of HR-HPV in young women, emphasizing the importance of vaccinating young girls before sexual debut.

show abstract

Section: Discussionsupporting

confidence: 93%

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, the association between HPV clearance and hormonal contraceptive use has been found to be inconsistent across studies. Studies involving college-aged women (Richardson et al, 2005;Sycuro et al, 2008) and high-risk adolescent women (Shew et al, 2006), which had limited sample sizes (N = 400), found no association between HPV persistence and current oral contraceptive use; however, other large population-based studies on women did report an association between current oral contraceptive use and an increased risk of viral persistence (Marks et al, 2011).…”

Section: Epidemiology Of Human Papillomavirus Infectionsmentioning

confidence: 92%

“…Increased metaplastic activity in the cervix during adolescence and its decline after menopause implica earlier age at sexual debut as a risk factor for HPV infection. Other factors related to HPV infection or persistence include young age, the socioeconomic status, multiparity, male circumcision, condom use, oral contraceptive use, smoking, immune suppression, viral load, and certain genetic polymorphisms 26, 91, 73, 89, 34, 32, 71, 83, 86, 30 40, 62, 82, 69, 68, 11, 67, 35, 61 90, 72, 66, 54, 6, 84, 59, 43 44, 31, 42, 45, 74, 33, 81, 70 51, 58, 53, 56 52 18 16 in the human leukocyte antigen system (Moscicki et al, 2001;Palefsky et al, 2001;Maciag et al, 2002;Schlecht et al, 2002;Richardson et al, 2003;Winer et al, 2003;Baldwin et al, 2004;Baseman and Koutsky, 2005;Cotton et al, 2007;Goodman et al, 2008;Tobian et al, 2009;Tobian et al, 2010;Marks et al, 2011;Bahmanyar et al, 2012;Emeka et al, 2012;Liao et al, 2012;Repp et al, 2012;Schabath et al, 2012;Teixeira et al, 2012;Zhang et al, 2012).…”

Section: Epidemiology Of Human Papillomavirus Infectionsmentioning

confidence: 99%

Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection

Asiaf

Ahmad

Mohammad

et al. 2014

European Journal of Cancer Prevention

102

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is a central and necessary, although not sufficient, cause of cervical cancer. Besides HPV, the additional multiple risk factors related with the onset of cervical cancer are early-age sexual activities; high number of sexual partners, which is the most salient risk factor; suppression and alteration of the immune status; long-term use of oral contraceptives; and other hormonal influences. The tumor-suppressor proteins p53 and pRb are degraded and destabilized through ubiquitination by viral oncoproteins E6 and E7. Over 95% of cervical cancer cases worldwide test positive for oncogenic HPV DNA. Although cervical screening procedures have been successful in reducing the disease burden associated with HPV infection because of lack of resources or inadequate infrastructure many countries have failed to reduce cervical cancer mortality. Therefore, prevention may be a valuable strategy for reducing the economic and disease burden of HPV infection. At present, two successful prophylactic HPV vaccines are available, quadrivalent (HPV16/18/6/11) 'Gardasil' and bivalent (HPV16/18) 'Cervarix' for vaccinating young adolescent girls at or before the onset of puberty. Recent data indicate that vaccination prevents the development of cervical lesions in women who have not already acquired the vaccine-specific HPV types. Moreover, several therapeutic vaccines that are protein/peptide-based, DNA-based, or cell-based are in clinical trials but are yet to establish their efficacy; these vaccines are likely to provide important future health benefits. The therapeutic vaccination mode of prevention is a promising area of research, as revealed in preclinical trials; however, clinical trials based on large populations are warranted before reaching a valid conclusion. This review summarizes the studies on the epidemiology of HPV infection, the pathogenesis of viral oncoproteins in the oncogenesis of cervical cancer, the economic and health burden of HPV-related diseases, and, finally, focuses on the results of recent clinical vaccination trials.

show abstract

“…In contrast, a South African case-control study found no association between recent users of oral contraceptives (compared to never users) and cervical cancer[25]. Other studies have found associations of oral contraceptives with increased prevalence [26,27] and persistence [28] of HPV.…”

Section: Introductionmentioning

confidence: 99%

Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa

et al. 2014

View full text Add to dashboard Cite

Background Few data exist regarding the effect of hormonal contraception (HC) on incidence and progression of cervical disease (e.g., cervical dysplasia, squamous intraepithelial lesions, cervical intraepithelial neoplasia) in HIV-infected African women. Study Design We conducted an observational study of HIV-seropositive women in Johannesburg, South Africa. The effect of individual HC types on the incidence and progression of cervical disease was determined using Poisson regression to obtain adjusted incidence rate ratios (IRR). Results We evaluated 594 HIV-infected women, with median follow-up time of 445 days; 75 of these women were receiving some form of hormonal contraception (largely DMPA, NET-EN, or COCs) at baseline. Risks of incidence and progression of cervical disease were similar comparing women not receiving HCs to women receiving DMPA, NET-EN, or COCs both individually by HC-type and considering all HC together. Conclusions There was no statistically significant effect of particular HC methods or of HC use in general on rates of incidence or progression of cervical disease in this study. These results should reassure us that use of HC is unlikely to substantially increase risks of cervical disease among HIV-positive women.

show abstract

Combined Oral Contraceptive Use Increases HPV Persistence but Not New HPV Detection in a Cohort of Women From Thailand

Cited by 35 publications

References 33 publications

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica

Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection

Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa

Contact Info

Product

Resources

About